新药Duvakitug在治疗高血压结肠炎和克罗恩病方面显示出可喜的成果。 New drug duvakitug shows promising results in treating ulcerative colitis and Crohn's disease.

最近的研究结果表明,Duvakitug(一种治疗中度至重度低温结肠炎和克罗恩病的新药)取得了可喜的成果。 Recent study results show promising outcomes for duvakitug, a new drug for treating moderate-to-severe ulcerative colitis and Crohn's disease. 在试验中,与安慰剂相比,duvakitug的缓解和反应率更高,没有重大安全问题. In trials, duvakitug achieved higher remission and response rates compared to placebo, with no major safety concerns. 药物由赛诺菲和特瓦制药公司开发,在测试的最高剂量下,性结肠炎的缓解率为48%,克罗恩病的反应率为48%. The drug, developed by Sanofi and Teva Pharmaceuticals, showed remission rates of 48% in ulcerative colitis and 48% response rates in Crohn's disease at the highest dose tested. 这些结果将为预计今年晚些时候开始的第三阶段方案提供信息。 These results will inform a phase 3 program expected to start later this year.